723 related articles for article (PubMed ID: 24211427)
1. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
Jobke B; Milovanovic P; Amling M; Busse B
Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
[TBL] [Abstract][Full Text] [Related]
2. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
3. Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
Moran EL; Fornasier TL; Bogoch TR
J Orthop Res; 2000 Nov; 18(6):873-81. PubMed ID: 11192246
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
Väänänen K
Adv Drug Deliv Rev; 2005 May; 57(7):959-71. PubMed ID: 15876398
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
Miki T; Minamide T
Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Hussein O; Tiedemann K; Komarova SV
Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
[TBL] [Abstract][Full Text] [Related]
7. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
8. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
Kellinsalmi M; Mönkkönen H; Mönkkönen J; Leskelä HV; Parikka V; Hämäläinen M; Lehenkari P
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition.
Drake MT; Cremers SC
Mol Interv; 2010 Jun; 10(3):141-52. PubMed ID: 20539033
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
Li B; Ling Chau JF; Wang X; Leong WF
J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
[TBL] [Abstract][Full Text] [Related]
11. Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone.
Allen MR; Erickson AM; Wang X; Burr DB; Martin RB; Hazelwood SJ
Calcif Tissue Int; 2010 Jan; 86(1):67-71. PubMed ID: 19953232
[TBL] [Abstract][Full Text] [Related]
12. YC-1 alleviates bone loss in ovariectomized rats by inhibiting bone resorption and inducing extrinsic apoptosis in osteoclasts.
Wang JW; Yeh CB; Chou SJ; Lu KC; Chu TH; Chen WY; Chien JL; Yen MH; Chen TH; Shyu JF
J Bone Miner Metab; 2018 Sep; 36(5):508-518. PubMed ID: 28983668
[TBL] [Abstract][Full Text] [Related]
13. Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality.
Neutzsky-Wulff AV; Sørensen MG; Kocijancic D; Leeming DJ; Dziegiel MH; Karsdal MA; Henriksen K
BMC Musculoskelet Disord; 2010 Jun; 11():109. PubMed ID: 20515459
[TBL] [Abstract][Full Text] [Related]
14. Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis.
Verdrengh M; Carlsten H; Ohlsson C; Tarkowski A
J Orthop Res; 2007 Mar; 25(3):304-10. PubMed ID: 17089391
[TBL] [Abstract][Full Text] [Related]
15. [Current topics in drug therapy aiming at bone resorption].
Yasui T; Tanaka S
Clin Calcium; 2006 Sep; 16(9):1475-79. PubMed ID: 16951471
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment.
Xu Q; Zhan P; Li X; Mo F; Xu H; Liu Y; Lai Q; Zhang B; Dai M; Liu X
J Cell Mol Med; 2021 Nov; 25(21):10126-10139. PubMed ID: 34651433
[TBL] [Abstract][Full Text] [Related]
17. Differences in osteoclast formation between proximal and distal tibial osteoporosis in rats with adjuvant arthritis: inhibitory effects of bisphosphonates on osteoclasts.
Shu G; Yamamoto K; Nagashima M
Mod Rheumatol; 2006; 16(6):343-9. PubMed ID: 17164994
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of the bisphosphonates.
Fleisch H
Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
[TBL] [Abstract][Full Text] [Related]
19. Denosumab and bisphosphonates: different mechanisms of action and effects.
Baron R; Ferrari S; Russell RG
Bone; 2011 Apr; 48(4):677-92. PubMed ID: 21145999
[TBL] [Abstract][Full Text] [Related]
20. Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis.
Li CY; Price C; Delisser K; Nasser P; Laudier D; Clement M; Jepsen KJ; Schaffler MB
J Bone Miner Res; 2005 Jan; 20(1):117-24. PubMed ID: 15619677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
